Astrazeneca Phar

Why is Astrazeneca Pharma India Ltd falling/rising?

As of 23-Jun, Astrazeneca Pharma India Ltd's stock price is declining, currently at 8,503.30, with a year-to-date drop of 5.62%. The company's financial results show a decrease in profit and high valuation metrics, suggesting poor long-term growth prospects despite increased investor participation.

As of 23-Jun, Astrazeneca Pharma India Ltd's stock price is falling, currently at 8,503.30, reflecting a decrease of 53.25 (-0.62%). This decline is evident in the company's recent performance, where it has underperformed its sector by 1.53% today. Over the past month, the stock has decreased by 1.17%, while the benchmark Sensex has increased by 1.04%. Year-to-date, the stock has dropped by 5.62%, contrasting with a 10.58% decline in the Sensex.<BR><BR>The company's financial results have also contributed to the negative sentiment. In the most recent quarter, the profit before tax (PBT) fell by 12.6% compared to the previous four-quarter average, and the profit after tax (PAT) decreased by 12.2%. Additionally, despite a high return on equity (ROE) of 21.62%, the stock is considered expensive with a price-to-book value of 26.6, which is above its peers' average historical valuations. This high valuation, combined with a flat operating profit growth rate of 15.14% over the last five years and a year-over-year profit decline of 5.3%, suggests poor long-term growth prospects.<BR><BR>While there has been a rise in investor participation, as indicated by a 92.46% increase in delivery volume, the overall performance metrics and financial results indicate that the stock is facing downward pressure.

Which are the latest news on Astrazeneca Phar?

How big is Astrazeneca Phar?

As of 10th June, Astrazeneca Pharma India Ltd has a market capitalization of 21,076.00 Cr, with recent net sales of 2,275.58 Cr and a net profit of 187.52 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Astrazeneca Pharma India Ltd has a market capitalization of 21,076.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 2,275.58 Cr, while the sum of Net Profit for the same period is 187.52 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds are valued at 770.35 Cr, and Total Assets amount to 1,476.56 Cr.

Who are in the management team of Astrazeneca Phar?

The management team of Astrazeneca Phar includes Chairman Narayan K Seshadri, CFO Rajesh Marwaha, Managing Director Sanjeev Panchal, and several Non-Executive and Independent Directors. They are responsible for the company's strategic direction and operations.

The management team of Astrazeneca Phar includes the following members:<BR><BR>1. **Narayan K Seshadri** - Chairman & Independent Director<BR>2. **Revathy Ashok** - Non-Executive & Independent Director<BR>3. **Rajesh Marwaha** - Whole Time Director & CFO<BR>4. **Weiying Sarah Wang** - Non-Executive Director<BR>5. **Ankush Nandra** - Non-Executive Director<BR>6. **Shilpa Divekar Nirula** - Non-Executive & Independent Director<BR>7. **Sanjeev Panchal** - Managing Director<BR>8. **Hooi Bien Chuah** - Non-Executive Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Who are the peers of the Astrazeneca Phar?

Astrazeneca Phar's peers include Wockhardt, Acutaas Chemical, Sai Life, Piramal Pharma, Neuland Labs, Pfizer, Granules India, ERIS Lifescience, and OneSource Speci. Acutaas Chemical and Sai Life show excellent growth and management risk, while Astrazeneca Phar has below-average growth and a slightly better 1-year return than Piramal Pharma.

Peers: The peers of Astrazeneca Phar are Wockhardt, Acutaas Chemical, Sai Life, Piramal Pharma, Neuland Labs., Pfizer, Granules India, ERIS Lifescience, and OneSource Speci.<BR><BR>Quality Snapshot: Excellent management risk is observed at Acutaas Chemical, Sai Life, Neuland Labs., and Pfizer, while Average management risk is found at Wockhardt, Piramal Pharma, and Astrazeneca Phar, and the rest. Growth is Excellent for Acutaas Chemical and Sai Life, Good for Neuland Labs. and Pfizer, Average for Wockhardt and Piramal Pharma, and Below Average for Astrazeneca Phar and the rest. Capital Structure is Excellent at Acutaas Chemical, Sai Life, Neuland Labs., Astrazeneca Phar, Pfizer, and Granules India, while Below Average is noted for Wockhardt and Piramal Pharma, and the rest have Good or Below Average ratings.<BR><BR>Return Snapshot: Acutaas Chemical has the highest 1-year return at 186.50%, while Piramal Pharma has the lowest at -19.58%, with Astrazeneca Phar's own 1-year return at -16.73%, indicating it is slightly better than Piramal Pharma. Additionally, the six-month return is negative for Piramal Pharma, ERIS Lifescience, and Astrazeneca Phar.

What does Astrazeneca Phar do?

AstraZeneca Pharma India Ltd manufactures, distributes, and markets pharmaceutical products, with a market cap of INR 21,076 Cr and net sales of 579 Cr reported for March 2026. Key metrics include a P/E ratio of 108.00 and a return on equity of 23.97%.

Overview:<BR>AstraZeneca Pharma India Ltd is engaged in the manufacture, distribution, and marketing of pharmaceutical products within the Pharmaceuticals & Biotechnology industry, classified as a small-cap company.<BR><BR>History:<BR>The company was incorporated on July 11, 1979. The latest quarterly results reported are for March 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 579 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 45 Cr (Quarterly Results - Mar 2026)<BR>- Market cap: INR 21,076 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 108.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.38%<BR>- Debt Equity: -0.46<BR>- Return on Equity: 23.97%<BR>- Price to Book: 26.49<BR><BR>Contact Details:<BR>Address: Blk N1 12th Flr Manyata Embass, Rachenahalli Outer Ring Road Bangalore Karnataka : 560045<BR>Tel: 91-080-67748000<BR>Email: comp.secy@astrazeneca.com<BR>Website: http://www.astrazeneca.in

Should I buy, sell or hold Astrazeneca Pharma India Ltd?

Are Astrazeneca Pharma India Ltd latest results good or bad?

AstraZeneca Pharma India Ltd's latest results show strong revenue growth of 20.42%, reaching ₹578.61 crores, but a concerning decline in net profit by 22.96% and a significant drop in operating margin to 10.53%, indicating potential cost management issues. Overall, the results are more concerning than positive.

AstraZeneca Pharma India Ltd's latest results present a mixed picture. On the positive side, the company reported a notable revenue growth of 20.42% year-over-year, reaching net sales of ₹578.61 crores in Q4 FY26. This indicates that the company is successfully expanding its market presence and product offerings.<BR><BR>However, the profitability metrics raise significant concerns. The net profit for the quarter was ₹44.88 crores, which reflects a sharp decline of 22.96% compared to the previous quarter and a similar drop of 22.95% year-over-year. This decline in profit occurred despite the strong revenue growth, suggesting that the company is facing challenges in managing costs effectively.<BR><BR>Moreover, the operating margin has compressed significantly to 10.53%, down from 17.98% in the same quarter last year. This substantial margin erosion indicates potential structural issues within the company, particularly related to rising costs.<BR><BR>Overall, while AstraZeneca Pharma India Ltd shows strong revenue growth, the declining profitability and significant margin compression suggest that the latest results are more concerning than positive. Investors may need to closely monitor the company's ability to manage costs and improve profitability in future quarters.

When is the next results date for Astrazeneca Pharma India Ltd?

The next results date for Astrazeneca Pharma India Ltd is 26 May 2026.

The next results date for Astrazeneca Pharma India Ltd is scheduled for 26 May 2026.

Is Astrazeneca Phar technically bullish or bearish?

As of November 7, 2025, the trend is mildly bullish, supported by positive MACD readings and moving averages, despite mixed signals from the KST and recent price declines, with strong long-term returns over 3 and 5 years.

As of 7 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by weekly and monthly MACD readings indicating bullish momentum. The Bollinger Bands and moving averages also reflect a mildly bullish outlook on the daily time frame. However, the KST shows a mixed signal with a bullish weekly but mildly bearish monthly reading. The Dow Theory aligns with a mildly bullish stance on both weekly and monthly charts. Despite recent price declines, the longer-term returns remain strong, particularly over 3 years and 5 years, indicating resilience in the stock.

How has been the historical performance of Astrazeneca Phar?

Astrazeneca Phar has shown significant growth in net sales, reaching 1,716.29 Cr in March 2025, up from 1,002.97 Cr in March 2023, despite a decline in profit margins and earnings per share. Total assets and liabilities increased to 1,476.56 Cr, while cash and cash equivalents rose to 536.70 Cr, indicating improved cash flow.

Answer:<BR>The historical performance of Astrazeneca Phar shows a significant growth trend in net sales and profits over the years, with net sales reaching 1,716.29 Cr in March 2025, up from 1,295.53 Cr in March 2024 and 1,002.97 Cr in March 2023. The total operating income followed a similar trajectory, increasing to 1,716.29 Cr in March 2025 from 1,295.53 Cr in March 2024. However, total expenditure also rose to 1,462.32 Cr in March 2025, compared to 1,111.08 Cr in March 2024, leading to an operating profit of 294.60 Cr in March 2025, up from 219.25 Cr in March 2024. Profit before tax decreased to 156.36 Cr in March 2025 from 219.54 Cr in March 2024, while profit after tax was 115.74 Cr in March 2025, down from 161.51 Cr in March 2024. The earnings per share (EPS) also saw a decline to 46.3 in March 2025 from 64.6 in March 2024. <BR><BR>In terms of assets and liabilities, total assets increased to 1,476.56 Cr in March 2025 from 1,056.78 Cr in March 2024, while total liabilities also rose to 1,476.56 Cr in March 2025 from 1,056.78 Cr in March 2024. The company maintained a strong cash position, with cash and cash equivalents rising to 536.70 Cr in March 2025 from 505.84 Cr in March 2024. The net cash inflow for March 2025 was 30.00 Cr, compared to 5.00 Cr in March 2024, indicating improved cash flow from operations. Overall, Astrazeneca Phar has demonstrated robust growth in sales and assets, despite fluctuations in profit margins and earnings per share.<BR><BR>Breakdown:<BR>Astrazeneca Phar has shown a strong upward trend in net sales, which increased from 1,002.97 Cr in March 2023 to 1,716.29 Cr in March 2025. This growth in revenue has been accompanied by a rise in total operating income, which reached 1,716.29 Cr in March 2025. However, the total expenditure also increased significantly, leading to an operating profit of 294.60 Cr in March 2025, a rise from 219.25 Cr in March 2024. Despite this, profit before tax saw a decline to 156.36 Cr in March 2025, down from 219.54 Cr in the previous year, and profit after tax also decreased to 115.74 Cr. The earnings per share reflected this trend, dropping to 46.3 in March 2025 from 64.6 in March 2024. On the balance sheet, total assets grew to 1,476.56 Cr in March 2025, while total liabilities matched this figure, indicating a balanced growth in both assets and liabilities. The company maintained a healthy cash position, with cash and cash equivalents increasing to 536.70 Cr, and a net cash inflow of 30.00 Cr in March 2025 suggests improved operational cash flow.

Is Astrazeneca Phar overvalued or undervalued?

As of March 31, 2020, Astrazeneca Phar is considered very expensive with a PE ratio of 120.70, significantly higher than peers like Sun Pharma and Divi's Lab, indicating overvaluation despite strong stock performance.

As of 31 March 2020, Astrazeneca Phar's valuation grade moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued, with a PE ratio of 120.70, an EV to EBITDA ratio of 94.10, and a PEG ratio of 3.45. These ratios highlight a premium valuation compared to its peers, such as Sun Pharma, which has a PE ratio of 35.25, and Divi's Lab, with a PE ratio of 79.33.<BR><BR>The peer comparison further emphasizes Astrazeneca Phar's elevated valuation, as it stands out with its very expensive classification against a backdrop of peers that are either expensive or attractive. Additionally, the company's strong performance in stock returns, significantly outpacing the Sensex over various timeframes, reinforces the notion of overvaluation, as investors may be pricing in future growth that may not be sustainable at current levels.

Who are the top shareholders of the Astrazeneca Phar?

The top shareholders of Astrazeneca Phar include Astrazeneca Pharmaceuticals Ab with 75.0%, Nippon Life India Trustee Ltd at 2.92%, mutual funds holding 4.45%, foreign institutional investors at 2.89%, and individual investors with 15.16%.

The top shareholders of Astrazeneca Phar include Astrazeneca Pharmaceuticals Ab, which holds a significant 75.0% of the shares. Other notable shareholders are Nippon Life India Trustee Ltd, representing the Nippon India Small Cap Fund across various schemes, with a holding of 2.92%. Additionally, mutual funds collectively hold 4.45% through 53 schemes, and foreign institutional investors (FIIs) own 2.89% across 95 entities. Individual investors also have a notable presence, holding 15.16% of the shares.

Has Astrazeneca Phar declared dividend?

Astrazeneca Pharma India Ltd has declared a 1200% dividend, amounting to ₹24 per share, with an ex-date of July 5, 2024. The company has shown strong price appreciation over various periods, with total returns of up to 233.77% over three years, despite low dividend yields.

Astrazeneca Pharma India Ltd has declared a 1200% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1200%<BR>- Amount per share: 24<BR>- Ex-date: 05 Jul 24<BR><BR>Dividend Yield: 0.24%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 48.19%, with a dividend return of 0%, resulting in a total return of 48.19%.<BR><BR>Over the past year, the price return was 58.09%, with a dividend return of 0.38%, leading to a total return of 58.47%.<BR><BR>In the 2-year period, the price return was 181.37%, with a dividend return of 1.10%, culminating in a total return of 182.47%.<BR><BR>For the 3-year period, the price return was 232.0%, with a dividend return of 1.77%, resulting in a total return of 233.77%.<BR><BR>In the last 4 years, the price return was 158.33%, with a dividend return of 1.37%, leading to a total return of 159.7%.<BR><BR>Over the past 5 years, the price return was 208.87%, with a dividend return of 1.47%, culminating in a total return of 210.34%.<BR><BR>Overall, Astrazeneca Pharma India Ltd has declared a significant dividend, and the total returns across various periods indicate strong price appreciation, particularly over longer time frames, despite relatively low dividend returns in the short term.